SCHEMBL866306

SCHEMBL866306

O=c1ccc2c([C@@H]3CO3)ccc(OCc3ccccc3)c2[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 1/20 0.44
ADORA3 P0DMS8 1/20 0.41
SIRT2 Q8IXJ6 1/20 0.37
ADAMTS5 Q9UNA0 1/20 0.37
HTR1A P08908 1/20 0.37
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
SRD5A2 P31213 1/20 0.37
LTA4H P09960 1/20 0.36
PLA2G2A P14555 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
TNKS2 Q9H2K2 1/20 0.36
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
MAOB P27338 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL632919 1.00 PIK3CG (0.44) PIK3CGADORA3SIRT2ADAMTS5HTR1A
SCHEMBL865843 1.00 PIK3CG (0.44) PIK3CGADORA3SIRT2ADAMTS5HTR1A
SCHEMBL29634508 1.00 PIK3CG (0.44) PIK3CGADORA3SIRT2ADAMTS5HTR1A
SCHEMBL30092323 0.88 SLC6A4 (0.43) PIK3CGHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL25666164 0.88 SLC6A4 (0.43) PIK3CGHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL25666254 0.85 HTR1A (0.47) PIK3CGADORA3HTR1ASLC6A2SLC6A4
SCHEMBL866075 0.82 ADORA3 (0.45) PIK3CGADORA3SIRT2ADAMTS5SRD5A2
SCHEMBL14355700 0.80 MAPT (0.39) MAPTKDM4EALDH1A1POLBCA9
SCHEMBL24689334 0.79 ADORA3 (0.43) PIK3CGADORA3SIRT2LTA4HPLA2G2A
SCHEMBL24689336 0.79 FEN1 (0.42) PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240208951-A1 A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF GBR LABORATORIES PRIVATE LIMITED (IN) 2024-06-27 US disclosed
US-20240208951-A1 A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF GBR LABORATORIES PRIVATE LIMITED (IN) 2024-06-27 US disclosed
US-20230322745-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-10-12 US disclosed
EP-4219485-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2023-08-02 EP disclosed
WO-2023077678-A1 SMALL MOLECULE COMPOUND TARGETING SRSF6 PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国药科大学 2023-05-11 WO disclosed
WO-2023077678-A1 SMALL MOLECULE COMPOUND TARGETING SRSF6 PROTEIN AND PREPARATION METHOD THEREFOR AND USE THEREOF 中国药科大学 2023-05-11 WO disclosed
CN-115677577-A Small molecular compound targeting SRSF6 protein, and preparation method and application thereof 中国药科大学 2023-02-03 CN disclosed
WO-2022172292-A1 A PROCESS FOR PREPARING ABEDITEROL AND INTERMEDIATES THEREOF GBR LABORATORIES PRIVATE LIMITED (IN) 2022-08-18 WO disclosed
CN-114591236-A Improved preparation method of indacaterol 四川海思科制药有限公司 2022-06-07 CN disclosed
CN-109721534-B Indacaterol maleate intermediate and preparation method and application thereof 四川海思科制药有限公司 2022-05-20 CN disclosed
WO-2004087142-A1 QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES NOVARTIS AG (CH) 2004-10-14 WO disclosed
US-6800643-B2 CORTICOSTEROID AND AN INDANYL-QUINOLINONE COMPOUND NOVARTIS AG (CH) 2004-10-05 US disclosed
WO-2004037773-A1 PHENETHANOLAMINE DERIVATIVE FOR THE TREATMENT OF RESPIRATORY DISEASES GLAXO GROUP LIMITED (GB) 2004-05-06 WO disclosed
US-20040038951-A1 Organic compounds NOVARTIS AG (CH) 2004-02-26 US disclosed
WO-2004016578-A2 ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-02-26 WO disclosed
EP-1341542-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2003-09-10 EP disclosed
WO-2002045703-A2 MIXTURES OR ORGANIC COMPOUNDS FOR THE TREATMENTOF AIRWAY DISEASES NOVARTIS AG (CH) 2002-06-13 WO disclosed
US-5750701-A Heterocyclic ethanolamine derivatives with β-adrenoreceptor agonistic activity SMITHKLINE BEECHAM PLC (GB) 1998-05-12 US disclosed
EP-0750617-A1 NOVEL HETEROCYCLIC ETHANOLAMINE DERIVATIVES WITH BETA-ADRENORECEPTOR AGONISTIC ACTIVITY SMITHKLINE BEECHAM PLC (GB) 1997-01-02 EP disclosed
WO-1995025104-A1 NOVEL HETEROCYCLIC ETHANOLAMINE DERIVATIVES WITH BETA-ADRENORECEPTOR AGONISTIC ACTIVITY SMITHKLINE BEECHAM P.L.C. (GB) 1995-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038951-A1 Organic compounds CYP11B2, NR3C2, CYP11B1 PIK3CG 4345/4885ADORA3 1485/4885SIRT2 4285/4885
US-20240208951-A1 A PROCESS FOR PREPARING NAVAFENTEROL AND INTERMEDIATES THEREOF CYP4A11, CYP4F11, XDH PIK3CG 3213/4885ADORA3 1755/4885SIRT2 2004/4885
US-20230322745-A1 FUSED TRICYCLIC DERIVATIVE AND PHARMACEUTICAL APPLICATION THEREOF CYP3A43, ABCB1, ABCB11 PIK3CG 2472/4885ADORA3 1321/4885SIRT2 1729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.